*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
We are leaders in immune biomarkers; our vision is to enable personalised, data-driven clinical decisions across the cancer care continuum. Using our unique expertise and proprietary technology we aim to transform the way disease is diagnosed and treated around the world. We know that detecting the disease early can improve the ability to treat cancer and enhance chances of survival.
Registrars:
Key Personnel
CEO:
Martin Gouldstone
Non-Executive Director:
John Goold
Non-Executive Chairman:
Alistair Macdonald
Senior Independent Non-Executive Director:
Sally Waterman
Contact Details
Address:
MediCity D6 Building, 1 Thane Road, Nottingham, United Kingdom